No doubt Pivalde will be pleased that Life Biosciences co...

First 14 Last

Share
Profile

Follow
skint

3,630 Posts.

116

28/12/18

19:30

Post #: 36976420
Share

Originally posted by skint: ↑

Great partner is right. THE LIFE BIOSCIENCES STORY

The only way to address the complexity of aging is by tackling each of the eight pathways that limit longevity and reduce healthspans.We have modeled our business accordingly by setting up individual Daughter companies to conduct their research independently and collaboratively. This itself is unprecedented. We are the first and largest company devoted to developing medicines for aging in its entirety. Each Daughter company was founded by the world’s leading scientists who work on the cutting-edge of aging research. Life Biosciences provides the capital, centralized management infrastructure and resources, acts as catalyst for ideas, insights and knowledge transfer, and provides advanced research facilities through its central lab in Cambridge, Mass. (USA).Another integral part of the Life Biosciences family is our technology company, Lua. Lua works to optimize the research of each Daughter company and enable Life Biosciences to derive critical data and insight across the organization. It is a leading HIPAA-compliant platform for patient-centric communication. Lua will allow for rapid data analysis and artificial intelligence (AI) capabilities to enable faster commercialization.Life Biosciences was co-founded in 2017 by David A. Sinclair, PhD, AO, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, an investment professional who developed its innovative company structure.THE STAKES COULD NOT BE HIGHERMillions of lives are being ended before their time. Productivity, joy and fulfillment are being cut short. The U.S. alone would save $4 trillion if people extended their heathspans and compressed the march of decline.

Expand

No doubt Pivalde will be pleased that Life Biosciences co founder David Sinclair is into mitochondria.
Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.
David Andrew Sinclair, Ph.D.Nature reviews. Cardiology, January 1, 2019

PBT Price at posting: 3.4¢ Sentiment: None Disclosure: Not Held
5 Upvote

0 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

There are more pages in this discussion • 8 more messages in this thread...

First 14 Last

Add PBT (ASX) to my watchlist

No doubt Pivalde will be pleased that Life Biosciences co...

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Sales growth pushes Lovisa's fortunes (and shares) upwards

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Featured News